Cannacord research note27 Feb 2025 07:48
Cannacord Genuity have issued a new research note today titled”Renewals improve visibility”. They conclude:
Impact on forecasts: The renewals replace contracts with a similar value per annum but add visibility across a multi-year period. We make no changes to our forecasts. Valuation: Trades on a FY25E/26E EV/sales of just 0.1x which unfairly assumes a profitable, cash generative business goes bust, in our view. Instead, today's renewals provide evidence that Totally is well-placed for a recovery in momentum as customer budgets unlock. The upcoming publication of the NHS 10-year plan, expected in spring 2025, will likely be a key driver of this. We maintain our BUY rating and 20p price target.